SAN JOSE, Calif., Sept. 1, 2016 /PRNewswire/ -- MIODx announced today the establishment of the company's Science Advisory Board. "MIODx is honored to have this team of distinguished leaders in their fields as committed advisors," said M. Allen Northrup PhD FRSC, CEO of MIODx. "Their input has already benefited our strategic vision, and we expect it will accelerate our growth into the exciting field of critically needed medical diagnostics."
Joining the Science Advisory Board are Victor Weedn, MD JD, Chairman of the Department of Forensic Sciences at George Washington University and immediate President of the American Academy of Forensic Sciences (AAFS); Timothy O'Leary MD JD, former Director of the Biomedical Laboratory Research and Development Service of the Department of Veterans Administration. While in that role, Dr. O'Leary established the VA Million Veteran Program; Wayne Grody MD PhD, Professor in the Departments of Pathology & Laboratory Medicine, Pediatrics and Human Genetics at the UCLA School of Medicine. Dr. Grody is also the Director of the Diagnostic Molecular Pathology within the UCLA Medical Center; Lawrence Fong MD, Efim Guzik Distinguished Professor in Cancer biology at the UCSF Helen Diller Family Comprehensive Cancer Center where he co-leads the Cancer Immunotherapy Program. Dr. Fong has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and different immune checkpoint inhibitors, as well as serving on the editorial boards of the Journal of Clinical Oncology, Journal of Immunotherapy of Cancer, and Cancer Immunology Research; and Rajvir Dahiya, PhD Professor and Director, Urology Research Center, Department of Urology at UCSF. Dr. Dahiya also serves as a scientific reviewer and chairman of the United States Army Department of Defense medical research programs in prostate, breast and ovarian cancer.
MIODx is a privately held company pioneering the discovery of early detection and prognostic cancer biomarkers through the company's proprietary platforms. The company's VerifyDx™ platform utilizes a highly sensitive, multiplex PCR assay and advanced bioinformatics to interrogate multiple DNA and RNA pathways that are implicated in highly metastatic cancer. In addition to the VerifyDx™ platform, MIODx utilizes high throughput immuno-sequencing to generate information on T and B cell diversity that can be applied to monitoring a patient's response to immunotherapy, discover new targets for drug companies, or as a way to profile an individual's adaptive immune system over time.